IMRX - NASDAQ
Immuneering Corporation
$4.55
+3.4%Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
At a Glance
Live SnapshotImmuneering Corporation Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Immuneering Corporation Balance Sheet
IMRX • NASDAQ
| Immuneering Corporation Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
128.6M | 36.1M | 59.4M | 72.6M | 74.9M | 37.1M | 13.8M | |
44.2M | 0.0 | 26.3M | 32.9M | 74.3M | 0.0 | 0.0 | |
172.8M | 36.1M | 85.7M | 105.5M | 149.2M | 37.1M | 13.8M | |
0.0 | 0.0 | 0.0 | 12.4K | 246K | 500.1K | 209.9K | |
0.0 | 0.0 | 0.0 | 12.4K | 246K | 500.1K | 209.9K | |
0.0 | 0.0 | 0.0 | 0.0 | 2.9M | 141K | 71.2K | |
3.4M | 3.4M | 3.4M | 3.2M | 0.0 | 0.0 | 0.0 | |
176.2M | 39.6M | 89.1M | 108.7M | 152.3M | 37.7M | 14.1M | |
NON-CURRENT ASSETS | |||||||
4.3M | 4.8M | 5.4M | 5.8M | 6.1M | 677.5K | 35.3K | |
6.7M | 6.7M | 6.7M | 6.7M | 6.7M | 0.0 | 0.0 | |
321.1K | 350.4K | 379.7K | 408.9K | 439K | 0.0 | 0.0 | |
7M | 7M | 7.1M | 7.1M | 7.1M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 996.6K | 0.0 | 0.0 | |
44.5M | 1.3M | 1M | 743.7K | 102.1K | 14.3K | 0.0 | |
55.7M | 13.1M | 13.5M | 13.6M | 14.4M | 691.8K | 35.3K | |
232M | 52.7M | 102.6M | 122.4M | 166.7M | 38.4M | 14.1M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
1.5M | 2M | 2.1M | 3.2M | 1.4M | 1.5M | 294.9K | |
1.5M | 2M | 2.1M | 3.2M | 1.4M | 1.5M | 294.9K | |
0.0 | 1.4M | 1.5M | 869.9K | 1M | 535.3K | 91.6K | |
397.1K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 338.4K | 300.1K | 378.7K | 274K | 76.3K | 0.0 | |
8.1M | 3.8M | 3.9M | 3.7M | 2.9M | 163.7K | 118.7K | |
10.1M | 7.5M | 7.8M | 8.1M | 5.6M | 2.3M | 505.3K | |
NON-CURRENT LIABILITIES | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 58.1M | 20.1M | |
3.4M | 3.8M | 4.2M | 4.5M | 5.1M | 58.6M | 20.1M | |
3.4M | 4.2M | 4.5M | 4.8M | 5.4M | 621.1K | 0.0 | |
13.5M | 11.3M | 12M | 12.5M | 10.7M | 60.9M | 20.6M | |
SHAREHOLDERS' EQUITY | |||||||
64.6K | 31.1K | 29.3K | 26.4K | 26.3K | 5K | 5K | |
498.7M | 265.7M | 253.8M | 219.6M | 215.3M | 3.3M | 2.2M | |
-280.3M | -224.3M | -163.3M | -109.8M | -59.3M | -25.7M | -8.7M | |
81.3K | 0.0 | -778.0 | -30.1K | -49K | 0.0 | 0.0 | |
218.5M | 41.4M | 90.6M | 109.9M | 156M | -22.5M | -6.5M | |
218.5M | 41.4M | 90.6M | 109.9M | 156M | -22.5M | -6.5M | |
SUMMARY | |||||||
232M | 52.7M | 102.6M | 122.4M | 166.7M | 38.4M | 14.1M | |
44.2M | 0.0 | 26.3M | 32.9M | 75.3M | 0.0 | 0.0 | |
3.8M | 4.2M | 4.5M | 4.8M | 5.4M | 621.1K | 0.0 | |
-124.8M | -32M | -54.9M | -67.8M | -69.5M | -36.5M | -13.8M | |
36,302,338 | 36,302,338 | 36,302,338 | 36,302,338 | 36,302,338 | 36,302,338 | 36,302,338 |
SEC Filings
IMRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | June 01, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | April 20, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 06, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 25, 2025 | September 24, 2025 | 2025 |
Related Guides
Continue your IMRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.